Johnson & Johnson
General ticker "JNJ" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $490.0B (TTM average)
Johnson & Johnson follows the US Stock Market performance with the rate: 27.1%.
Estimated limits based on current volatility of 1.4%: low 269.05$, high 276.79$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2026-08-25, amount 1.34$ (Y1.93%)
- Total employees count: 140800 (+0.7%) as of 2025
- US accounted for 60.7% of revenue in the fiscal year ended 2023-01-01
- Top business risk factors: Market competition, Patent expiration, Regulatory and compliance, Public health crises, Litigation risks
- Current price 25.4% above estimated high
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-28 to 2027-12-28
- 2025-12-28 to 2026-12-28 estimated range: [161.25$, 222.07$]
- 2026-12-28 to 2027-12-28 estimated range: [176.94$, 240.42$]
Financial Metrics affecting the JNJ estimates:
- Negative: with PPE of 19.2 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 32.10 > 18.77
- Positive: 18.97 < Shareholder equity ratio, % of 40.93 <= 42.26
- Positive: Industry operating profit margin (median), % of 24.68 > 9.99
- Positive: Industry earnings per price (median), % of 6.62 > 4.32
- Positive: 0.28 < Operating cash flow per share per price, % of 4.86
- Positive: Return on assets ratio (scaled to [-100,100]) of 11.86 > 6.06
- Positive: Interest expense per share per price, % of 0.19 <= 0.75
- Positive: 5.56 < Industry operating cash flow per share per price (median), % of 5.63
Short-term JNJ quotes
Long-term JNJ plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-29 | 2025-12-28 |
|---|---|---|---|
| Operating Revenue | $79,014.00MM | $88,821.00MM | $101,487.00MM |
| Operating Expenses | $63,952.00MM | $66,672.00MM | $68,906.00MM |
| Operating Income | $15,062.00MM | $22,149.00MM | $32,581.00MM |
| Non-Operating Income | $0.00MM | $-5,462.00MM | $0.00MM |
| Interest Expense | $772.00MM | $755.00MM | $971.00MM |
| R&D Expense | $15,085.00MM | $17,232.00MM | $14,665.00MM |
| Income(Loss) | $15,062.00MM | $16,687.00MM | $32,581.00MM |
| Taxes | $1,736.00MM | $2,621.00MM | $5,777.00MM |
| Other Income(Loss) | $21,827.00MM | $0.00MM | $0.00MM |
| Net Income(Loss)* | $35,153.00MM | $14,066.00MM | $26,804.00MM |
| Stockholders Equity | $68,774.00MM | $71,490.00MM | $81,544.00MM |
| Inventory | $11,181.00MM | $12,444.00MM | $14,191.00MM |
| Assets | $167,558.00MM | $180,104.00MM | $199,210.00MM |
| Operating Cash Flow | $22,791.00MM | $24,266.00MM | $24,530.00MM |
| Capital expenditure | $4,543.00MM | $4,424.00MM | $4,832.00MM |
| Investing Cash Flow | $878.00MM | $-18,599.00MM | $-23,588.00MM |
| Financing Cash Flow | $-15,825.00MM | $-3,132.00MM | $-5,539.00MM |
| Earnings Per Share** | $13.88 | $5.84 | $11.04 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.